Tests LY4337713 in adults with advanced solid tumors that have high FAP protein
Tests radioligand therapy LY4337713 in adults with certain advanced cancers that have high FAP protein.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Boston, Dallas, Detroit, Durham, Glen Burnie, Grand Rapids, Houston, Indianapolis, Madison, Miami, New York, Newport Beach, Philadelphia, Rochester, St Louis, Stanford, and Tampa, United StatesSee the 20 sitesAlso in 4 other countries, 9 sites
- Trial code
- NCT07213791
- EU 2025-521887-37-00
- U1111-1332-3899
- Registry title
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 340 people, planned
- Started
- 22 Oct 2025
- Expected to end
- Mar 2033
- Type of study
- Interventional, 6 groups
- Treatments tested
- LY4337713
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spread solid tumors that show the protein FAP. Cancer types include pancreatic, breast, ovarian, stomach, colorectal, esophageal and bile duct cancer.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic solid cancer, confirmed by tissue or cell tests. Types: pancreatic adenocarcinoma, breast cancer (HR-positive HER2-negative, HER2-positive, or triple negative), platinum-resistant or refractory ovarian cancer, gastric cancer, colorectal cancer, esophageal cancer, cholangiocarcinoma, or other non-CNS solid tumors with FAP uptake on PET.
- Earlier treatment
- People must have had earlier cancer treatment, and the amount depends on the cancer type. Examples: pancreatic cancer needs at least 1 but no more than 2 earlier regimens; ovarian cancer needs at least 1 platinum-based therapy; gastric, colorectal, esophageal and bile duct cancer need at least 1 earlier systemic therapy. Phase 1b needs at least 1 earlier line of therapy.
- Biomarker or test result
- Clinical or imaging evidence of fibroblast activation protein (FAP) expression, by local assessment.
Main reasons for not taking part
- Active cancer in the brain or spinal fluid lining (CNS metastases or carcinomatous meningitis)
- Significant heart disease
- QTcF longer than 470 milliseconds on the heart tracing at screening
- Ongoing, untreated blockage of the urinary tract
- Earlier radiation to the whole body or half of the body, or earlier adoptive T-cell therapy such as CAR-T
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
- Must have histologically or cytologically confirmed diagnosis of one of the following:; Adenocarcinoma of the pancreas; Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer; HER2-positive breast cancer; Triple negative breast cancer (TNBC); Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma); Gastric cancer (adenocarcinoma); Colorectal cancer (CRC); Esophageal cancer (squamous cell carcinoma or adenocarcinoma); Cholangiocarcinoma; Other non- central nervous system (CNS) solid tumors, which have demonstrated FAP uptake via positron emission tomography (PET),
- Must have received prior treatments as indicated below:; Phase 1a; Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease; HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor; HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available); TNBC: Participants must have received at least 1 prior line of therapy for metastatic disease, and must have received an ADC unless unavailable, ineligible, or refused; Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy; Gastric cancer, CRC, esophageal cancer (squamous cell carcinoma or adenocarcinoma), and cholangiocarcinoma: Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; this may include, but does not require, prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor; Other non-CNS solid tumors: Participants must have exhausted, be ineligible for, or refused all standard-of-care therapy appropriate for their disease; Phase 1b:; Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy
- Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
- Measured creatinine clearance ≥60 milliliters per minute (mL/min)
Who cannot take part
- Had previous hemi- or total-body radiation
- Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T therapy, T-cell receptor [TCR] therapy, etc.)
- Have significant cardiovascular disease
- Have prolongation of the corrected QTcF >470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
- Have known active central nervous system (CNS) metastases or carcinomatous meningitis
- Have evidence of ongoing and untreated urinary tract obstruction
- Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI)
Where in United States
Also in 4 other countries, 9 sites
- Beth Israel Deaconess Medical CenterBoston, United StatesNot yet recruiting
- Massachusetts General HospitalBoston, United StatesTaking people
- Texas Oncology - DFW (Sammons CC)Dallas, United StatesTaking people
- Barbara Ann Karmanos Cancer InstituteDetroit, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- United TheranosticsGlen Burnie, United StatesTaking people
- BAMF Health Inc.Grand Rapids, United StatesTaking people
- Baylor College of MedicineHouston, United StatesNot yet recruiting
- Indiana University (IU) School of MedicineIndianapolis, United StatesTaking people
- University of Wisconsin Carbone Cancer CenterMadison, United StatesTaking people
- Biogenix Molecular, LLCMiami, United StatesNo longer taking part
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew York, United StatesTaking people
- New York University (NYU) Clinical Cancer CenterNew York, United StatesTaking people
- Hoag Memorial Hospital PresbyterianNewport Beach, United StatesTaking people
- Fox Chase Cancer CenterPhiladelphia, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- Washington University School of Medicine in St. LouisSt Louis, United StatesTaking people
- Stanford University Medical CenterStanford, United StatesTaking people
- MoffittTampa, United StatesTaking people
About the trial
What the trial wants to find out
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
The 6 groups in the trial
- LY4337713 (Cohort A1)Treatment being tested
Escalating doses of LY4337713 administered intravenously (IV).
Treatment: LY4337713
- LY4337713 (Cohort A2)Treatment being tested
Two or more dose regimens of LY4337713 (evaluated during dose escalation) administered IV.
Treatment: LY4337713
- LY4337713 (Cohort B)Treatment being tested
Tumor specific cohort will receive LY4337713 administered IV.
Treatment: LY4337713
- LY4337713 (Cohort C)Treatment being tested
Tumor specific cohort will receive LY4337713 administered IV.
Treatment: LY4337713
- LY4337713 (Cohort D)Treatment being tested
Tumor specific cohort will receive LY4337713 administered IV.
Treatment: LY4337713
- LY4337713 (Cohort E)Treatment being tested
Tumor specific cohort will receive LY4337713 administered IV.
Treatment: LY4337713
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
- Plain-language title
- Tests LY4337713 in adults with advanced solid tumors that have high FAP proteinGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026